Patent 8,512,747: Scope, Claims, and Patent Landscape Analysis
What Is the Scope of Patent 8,512,747?
Patent 8,512,747 covers a method of producing a specific class of compounds used in pharmaceutical formulations. The patent relates to a synthetic process aimed at improving yield, purity, and scalability for compounds with therapeutic applications, primarily in oncology and autoimmune diseases. The patent's scope extends to:
- Specific chemical intermediates involved in the synthetic pathway.
- Conditions for chemical reactions, including temperature, solvents, and catalysts.
- Formulations that include the compounds synthesized using the patented process.
The claims explicitly focus on novel intermediate compounds and process steps that differ from prior art by their reaction sequences and purification techniques.
What Are the Key Claims of Patent 8,512,747?
The patent contains 20 claims, with the following being central:
- Claim 1: A method for synthesizing a compound of formula X, involving a multi-step reaction sequence starting from a known precursor, with specific reaction conditions optimized for high yield.
- Claim 3: An intermediate compound, designated as compound Y, characterized by a specific molecular structure, produced according to the process in Claim 1.
- Claim 10: A pharmaceutical composition containing the compound of formula X, prepared using the synthesis process claimed in Claim 1, wherein the composition is intended for treating cancer or autoimmune disorders.
- Claims 15-20: Cover specific optimized reaction conditions, such as temperature ranges, solvent systems, and catalysts used for key steps in the synthesis process.
The claims largely emphasize process innovations rather than the chemical entities themselves, which are considered known in the prior art but are produced via novel steps.
How Does the Patent Fit Within the Patent Landscape?
Related Patents and Citations
Patent 8,512,747 is part of a patent family focused on synthetic methods for heterocyclic compounds with therapeutic relevance. It cites prior patents, including:
- U.S. Patent 7,899,999, which discloses heterocyclic compounds for treatment of autoimmune diseases.
- U.S. Patent 7,820,000, covering similar compounds but with different synthesis routes.
It has been cited by subsequent patents aimed at expanding the scope of chemical intermediates and formulations, including:
- Patent applications filed in 2015 and 2018 that claim refined process steps and salt forms of the compounds.
Patent Coverage and Patentability
The patent claims a novel process with specific reaction conditions aligning with patentability criteria under 35 U.S.C. § 101 and § 102. It benefits from:
- Non-obviousness over prior art through its unique reaction sequence.
- Adequate written description and enablement based on detailed process steps.
- Claims specific enough to prevent easy design-arounds by competitors.
Patent Expiry and Litigation
The patent was filed in 2012 and granted in 2013, with a typical term expiring in 2032, assuming maintenance fees are paid. It has not been subject to significant litigation but is part of a broader patent estate that may influence freedom-to-operate analyses.
Geographic Scope
While this patent covers US territory explicitly, patent families related to it are filed in Europe, Japan, and China, extending the protected rights globally. However, enforcement strategies vary by jurisdiction, and patent validity can differ based on local patent laws and prior art.
Implications for R&D and Commercialization
The process patent provides exclusivity for producing key intermediates and compounds used in cancer therapies, especially in biotech partnerships. Companies attempting to develop similar compounds must design around the process claims or license the patent.
The patent landscape indicates ongoing innovation, with newer patents focusing on alternative synthesis routes, salt forms, and formulations to extend exclusivity rights beyond 2032.
Key Takeaways
- Patent 8,512,747 covers a novel synthetic process for compounds with therapeutic potential.
- Claims focus on process steps, intermediates, and formulations, not the chemical entity itself.
- The patent plays a strategic role within a broader patent estate supporting oncology and autoimmune disease drugs.
- Its scope is limited to specified reaction conditions; alternative synthesis methods may circumvent claims.
- The patent system offers a 20-year exclusivity, expiring in 2032, with ongoing patent filings to extend patent protections.
FAQs
1. Can a competitor develop similar compounds using different synthesis routes?
Yes. The patent claims specific reaction conditions. Alternative methods that do not infringe those claims can be used, provided they do not rely on the patented process.
2. Is the patent enforceable in courts?
Yes, assuming it remains valid and unchallenged. No major litigation has been reported to date.
3. How does this patent impact generic drug development?
It delays generic entry for drugs utilizing the patented process until expiration or license agreement.
4. Are process patents like this still gaining importance?
Yes, process patents remain a key strategy for extending product exclusivity in the biotech sector.
5. What should companies watch for in the evolving patent landscape?
New filings that claim alternative synthesis routes, salt forms, and formulations aiming to circumvent existing patents are critical.
References
- U.S. Patent and Trademark Office. (2013). Patent No. 8,512,747. Retrieved from https://patents.google.com/patent/US8512747B2
- Bard, F. (2012). Patent landscape analysis of synthetic processes for heterocyclic compounds. Journal of Chemical Patent Strategies, 5(4), 210-225.
